MARKET

AGEN

AGEN

Agenus
NASDAQ
1.975
+0.095
+5.05%
Opening 13:02 06/08 EDT
OPEN
1.870
PREV CLOSE
1.880
HIGH
2.030
LOW
1.830
VOLUME
4.84M
TURNOVER
5.80M
52 WEEK HIGH
3.370
52 WEEK LOW
1.227
MARKET CAP
689.03M
P/E (TTM)
-2.4501
1D
5D
1M
3M
1Y
5Y
Analysts Are Bullish on Top Healthcare Stocks: Cue Biopharma (CUE), Agenus (AGEN)
TipRanks · 1d ago
Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2023
Benzinga · 2d ago
Baird Initiates Coverage of Agenus (AGEN) with Outperform Recommendation
NASDAQ · 2d ago
Baird Initiates Coverage On Agenus with Outperform Rating, Announces Price Target of $8
Benzinga · 2d ago
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga · 3d ago
Agenus: This Time May Be Different
Seeking Alpha · 3d ago
HC Wainwright & Co. Reiterates Agenus (AGEN) Buy Recommendation
NASDAQ · 3d ago
Analysts Offer Insights on Healthcare Companies: Agenus (AGEN) and Balchem (BCPC)
TipRanks · 3d ago
More
About AGEN
Agenus Inc. is a clinical-stage immuno-oncology (I-O) company. The Company is focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company’s I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy and vaccine adjuvants. The Company’s antibody candidates are botensilimab (a CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody). Botensilimab is in three Phase 2 studies as a monotherapy (melanoma), in combination with chemotherapy (pancreatic cancer), and in combination with balstilimab (microsatellite stable colorectal cancer (MSS CRC)). Its clinical-stage portfolio also includes Botensilimab (AGEN1181), Balstilimab (AGEN2034), Zalifrelimab (AGEN1884), AGEN2373, AGEN1423, AGEN1571, MK-4830, INCAGN1876, INCAGN2390, INCAGN2385, BMS-986442, UGN-301, agenT-797 and QS-21 STIMULON. AGEN2373, a CD137 monospecific antibody in a Phase 1b clinical trial.

Webull offers kinds of Agenus Inc stock information, including NASDAQ:AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.